Alliancebernstein L.P. Merus N.V. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Merus N.V. stock. As of the latest transaction made, Alliancebernstein L.P. holds 730,631 shares of MRUS stock, worth $36.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

730,631

Previous 678,021 7.76%

Holding current value

$36.3 Million

Previous $40.1 Million 9.01%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$47.19 - $58.84 $2.48 Million - $3.1 Million	52,610 Added 7.76%	730,631 $36.5 Million
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $23.7 Million - $35.8 Million	594,761 Added 714.34%	678,021 $40.1 Million
Q1 2024 May 14, 2024	SELL	$28.03 - $51.82 $2.41 Million - $4.45 Million	-85,838 Reduced 50.76%	83,260 $3.75 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $465,111 - $664,510	-23,186 Reduced 12.06%	169,098 $4.65 Million
Q3 2023 Nov 14, 2023	BUY	$20.13 - $27.29 $247,357 - $335,339	12,288 Added 6.83%	192,284 $4.53 Million
Q2 2023 Aug 15, 2023	SELL	$18.33 - $27.18 $640,670 - $949,995	-34,952 Reduced 16.26%	179,996 $4.74 Million
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $778,933 - $1.12 Million	54,662 Added 34.1%	214,948 $3.96 Million
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $1.3 Million - $2.4 Million	101,482 Added 172.58%	160,286 $2.48 Million
Q3 2022 Nov 15, 2022	SELL	$18.64 - $28.93 $261,127 - $405,280	-14,009 Reduced 19.24%	58,804 $1.18 Million
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $132,726 - $277,699	9,494 Added 14.99%	72,813 $1.65 Million
Q1 2022 May 13, 2022	SELL	$23.58 - $30.91 $165,885 - $217,451	-7,035 Reduced 10.0%	63,319 $1.67 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $1.41 Million - $2.27 Million	70,354 New	70,354 $2.24 Million

Others Institutions Holding MRUS

# of Institutions

200

Shares Held

61.9M

Call Options Held

243K

Put Options Held

300K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Merus N.V. Transaction History